Joseph P. O'Connell M.D. serves as Chief Medical Officer of the Company.D., is the Chief Medical Officer of Odonate Therapeutics Inc. Dr. O’Connell has served as our Chief Medical Officer since September 2017. From 2015 to 2017, Dr. O’Connell served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior Director and Asset Global Clinical Lead for Oncology. Prior to 2007, he practiced adult medical oncology for more than 15 years, most recently as a Medical Oncologist at the Yale Cancer Center. Dr. O’Connell received a B.S. degree in biology from Fordham University and an M.D. degree from the State University of New York.
As the Chief Medical Officer of Odonate Therapeutics Inc, the total compensation of Joseph Connell at Odonate Therapeutics Inc is $1,980,570. There are no executives at Odonate Therapeutics Inc getting paid more.
Joseph Connell is 65, he's been the Chief Medical Officer of Odonate Therapeutics Inc since 2017. There are 1 older and 10 younger executives at Odonate Therapeutics Inc. The oldest executive at Odonate Therapeutics Inc is Dr. Joseph P. O'Connell M.D., 66, who is the Chief Medical Officer.
Joseph's mailing address filed with the SEC is 4747 Executive Dr, San Diego, CA 92121, USA.
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis, eKevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: